



Pfizer Research Grant RFP

Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and Caregivers

Competitive Grant Program –Pfizer Internal Review Process



Overview

Projects that will be considered for Pfizer support will focus on quantifying the socio-economic burden of disease in atopic dermatitis, alopecia areata and/or vitiligo patients and their caregivers / with a goal of understanding if the current level of healthcare system resources matches the patient need.



Geographic Scope

Australia, Canada, Japan, France, Germany, Italy, Spain, UK, Austria, Belgium/Luxembourg, Denmark, Finland, Greece, Ireland, Netherlands, Norway, Sweden, Switzerland, Poland, Portugal, Romania, Czech Republic, Slovakia



Project Types and Area of Interest

Projects that will be considered for Pfizer support will focus on quantifying the socio-economic burden of disease in atopic dermatitis, alopecia areata and/or vitiligo patients and their caregivers / with a goal of understanding if the current level of healthcare system resources matches the patient need.

The socio-economic burden includes but is not limited to such costs as 1) time away from work or school for the patient or their caregivers 2) out of pocket expenditures for treatment or services 3) use of mental health services or treatments / absenteeism due to disease-related anxiety or depression 4) loss of academic or career opportunities 5) other quality-of-life impacts.

To understand and address this gap, Pfizer seeks to support research efforts that will quantify the burden of disease for atopic dermatitis and/or alopecia areata and advance the efforts of patient advocacy groups that hope to develop resources to address the burden.



Key Milestones

- Application submission deadline: 27 June 2023
- Anticipated decision notification date: August 2023
- Anticipated project start date: from December 2023, upon contract execution



Funding Range and Project Length

Individual projects requesting up to a maximum of \$50,000 – \$75,000 will be considered, for a duration of 1 year.

I. Eligibility

Geographic Scope:

- Australia, Canada, Japan, France, Germany, Italy, Spain, UK, Austria, Belgium/Luxembourg, Denmark, Finland, Greece, Ireland, Netherlands, Norway, Sweden, Switzerland, Poland, Portugal, Romania, Czech Republic, Slovakia

Applicant Eligibility Criteria

- The institution and principal investigator (PI) must be based in one of the eligible countries noted above.
- The Applicant (PI) must represent a registered dermatological patient organization or
- The applicant (PI) must be in partnership with a registered dermatological patient organization for this research and have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Social Work or Public Health.
- The Applicant (PI) must have appropriate skills and experience to conduct the research and must have adequate access to data sources. Appropriate skills and experience can include the execution of previous patient and carer productivity / QOL impact surveys or studies, policy white papers on impact of psychological dermatological diseases, burden of disease socio-economic analysis, studies and publications.
- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- Applicant must be affiliated with a host institution

II. Requirements

Date RFP Issued

- May 26, 2023

Clinical Area

- Dermatology (Atopic Dermatitis, Alopecia Areata, Vitiligo), Public Health, Direct and indirect costs, quality of life, socio-economic impact

General Area of Interest for this RFP:

- Due to a historical lack of comprehensive prevalence and incidence data for atopic dermatitis, alopecia areata and vitiligo, national healthcare authorities and stakeholders are unable to assess their full cost to society, and by extension, understand if the current policies for care and treatment address the true unmet need.
- Projects that will be considered for Pfizer support will focus on quantifying the socio-economic burden of disease in atopic dermatitis, alopecia areata and/or vitiligo patients and their caregivers / with a goal of understanding if the current level of healthcare system resources matches the patient need.
- The socio-economic burden includes but is not limited to such costs as 1) time away from work or school for the patient or their caregivers 2) out of pocket expenditures for treatment or services 3) use of mental health services or treatments / absenteeism due to disease-related anxiety or depression 4) loss of academic or career opportunities 5) other quality-of-life impacts.
- To understand and address this gap, Pfizer seeks to support research efforts that will quantify the burden of disease for atopic dermatitis alopecia areata and/or vitiligo and advance the efforts of patient advocacy groups that hope to develop resources to address the burden.

Requests for drug/compound will not be considered as part of this RFP.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to a maximum of \$50,000 – \$75,000 will be considered. The estimated total available budget related to this RFP is \$260,000.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- RFP release date: 26 May 2023
Grant Application due date: 27 June 2023
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: August 2023
- Grants will be distributed following a fully executed agreement and submission of Final Protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption or waiver (if applicable), to be received by December 2023.
- Anticipated Project Start and End Dates: from December 2023, upon contract execution, for a maximum of 1 year

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. *[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]*
- Click the “Start a New Research Grant Application” button.
- In the application:
- For the question “Competitive Grant?” select Yes
- Select the following Competitive Grant Program Name: 2023 I&I IDM Quantification of Socio-Economic Burden of Disease for Dermatological Patients and Caregivers RES
- Requirements for submission:
 - Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, AP Lee, at GMGEMEA@pfizer.com, with the subject line “2023 I&I IDM Quantification of Socio-Economic Burden of Disease for Dermatological Patients and Caregivers RES, May 2023.”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your

institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.

- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
- Payment will only be made to requesting Institution.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit [adjust as necessary] exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective

Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question

Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population

Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project

Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates
 - An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project

Budget Detail

- The budget amount requested must be in U.S. dollars (USD).
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as insurances, heating, lighting, rent, building maintenance may be included. Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.